Compare CSTE & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | GOSS |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 65.6M |
| IPO Year | 2012 | 2018 |
| Metric | CSTE | GOSS |
|---|---|---|
| Price | $2.98 | $10.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 53.0K | ★ 4.7M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,471,000.00 |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $2.83 | $201.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $0.11 |
| 52 Week High | $3.84 | $12.52 |
| Indicator | CSTE | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 79.61 |
| Support Level | $2.87 | $0.18 |
| Resistance Level | $3.33 | $12.52 |
| Average True Range (ATR) | 0.16 | 0.98 |
| MACD | -0.03 | 0.37 |
| Stochastic Oscillator | 29.05 | 86.51 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa), of which it derives maximum revenue from United States.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).